Short interest for 36KR Holdings gives investors a sense of the degree to which investors are betting on the decline of 36KR Holdings's stock. Short interest data is updated every two weeks.

36KR Holdings Stock (NASDAQ:KRKR), Short Interest Report

36KR Holdings

36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.

Long Ideas

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

CRGE

GPAK

KRKR

SHEN

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.

Top 5 Tech And Telecom Stocks That Are Set To Fly In Q4

Intraday Update

Movers

AFRM

AGRI

AIMD

AMTI

AVGO

AVGR

CALT

CFFE

CMRA

CSCO

CYTH

CZOO

DXYN

ELUT

EXAI

FUBO

GOOG

LIFW

LNZA

MAPS

MOND

MURF

MVLA

NEPT

OPEN

RNAZ

SEEL

SGBX

SPLK

SWIN

TVTX

UPTD

Gainers

MSP Recovery, Inc.  (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday.

Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

AEHL

AENT

ARBB

CRDL

FTEL

HSCS

KERN

VINE

VINO

Gainers

Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer.

Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

36Kr Holdings Inc. - American Depositary Shares

36KR Holdings Inc

The Food and Drug Administration (FDA) notified Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) on Friday that its review of a new vaccine <a href="https://www.benzinga.com/topic/vaccines">has been delayed</a>.
The agency, citing administrative constraints, does not expect to complete its review of the Biologics License Application (BLA) for mRNA-1345, Moderna&#8217;s investigational respiratory syncytial virus (RSV) vaccine, by the Prescription Drug User Fee Act <a href="https://www.benzinga.com/pressreleases/24/05/ac38756388/moderna-announces-update-on-investigational-rsv-vaccine" target="_blank" rel="noreferrer noopener">date of May 12, 2024</a>. 
The FDA has informed Moderna that it is working to conclude the review by the end of May 2024.
The FDA has not informed Moderna of any issues related to vaccine safety, efficacy, or quality that would prevent the approval of mRNA-1345.
Related: <a href="https://www.benzinga.com/general/biotech/24/05/38592653/moderna-reports-smaller-than-expected-q1-loss-prepares-for-rsv-vaccine-and-spikevax-2024-2025-for" target="_blank" rel="noreferrer noopener">Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars</a>.
Moderna remains on track for mRNA-1345 to be reviewed at the CDC&#8217;s Advisory Committee on Immunization Practices June 26-27, 2024, meeting, which is necessary before commercial launch.
In February,&nbsp;Moderna released&nbsp;a longer-term trial analysis that showed a faster decline in the effectiveness of its&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/37039381/why-is-moderna-stock-trading-lower-today" rel="noreferrer noopener">experimental RSV vaccine</a>.
Follow-up data from the Phase 3 mRNA-1345 Trial At ReSViNET suggests the vaccine efficacy is declining faster than RSV vaccines from&nbsp;GSK Plc&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)&nbsp;and&nbsp;Pfizer Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
The data showed that the efficacy of the mRNA-1345 vaccine was about 63% after 8.6 months, from 84% at 3.3 months.
Top-line data released a year ago&nbsp;<a target="_blank" href="https://news.modernatx.com/news/news-details/2023/Moderna-Announces-mRNA-1345-an-Investigational-Respiratory-Syncytial-Virus-RSV-Vaccine-Has-Met-Primary-Efficacy-Endpoints-in-Phase-3-Trial-in-Older-Adults/default.aspx" rel="noreferrer noopener">showed</a>&nbsp;that mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease.
William Blair&nbsp;writes that although regulatory delays are disappointing and usually create noise around the probability of approval, the update on Moderna&#8217;s RSV vaccine does not alter the expectation that mRNA-1345 will receive approval under the current review cycle.&nbsp;
Management has pinned the RSV vaccination target addressable market at about $10 billion.
The analyst models $1.46 billion in peak U.S. sales for mRNA-1345.
&#8220;The product remains an important contributor to Moderna&#8217;s return to growth in 2025 and 2026 breakeven story,&#8221; William Blair writes.&nbsp;&nbsp;
The analyst reiterates the Market Perform rating on Moderna shares.
Price Action: MRNA shares are down 2.20% at $119.99 during the premarket session at last check Friday.
Now Read: <a href="https://www.benzinga.com/general/biotech/24/05/38592653/moderna-reports-smaller-than-expected-q1-loss-prepares-for-rsv-vaccine-and-spikevax-2024-2025-for">Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars</a>
Image: Shutterstock

Biotech

Earnings

Large Cap

Health Care

General

MRNA

FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It

Dividends

Buybacks

Curtiss-Wright Boosts Share Repurchase Authorization By $300M To $400M, Increases Dividend From $0.20 To $0.21 Per Share

Piper Sandler analyst Matt O'Brien reiterates TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) with a Overweight and lowers the price target from $12 to $10.

Price Target

Reiteration

Analyst Ratings

TELA

Piper Sandler Reiterates Overweight on TELA Bio, Lowers Price Target to $10

Lake Street analyst Eric Martinuzzi downgrades Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) from Buy to Hold and lowers the price target from $6 to $3.5.

Downgrades

EVLV

Lake Street Downgrades Evolv Technologies to Hold, Lowers Price Target to $3.5

Wedbush analyst Jay McCanless reiterates CoreCivic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXW#NYSE">CXW</a>) with a Outperform and maintains $19 price target.

Wedbush Reiterates Outperform on CoreCivic, Maintains $19 Price Target

Piper Sandler analyst Jason Bednar reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Neutral and raises the price target from $220 to $225.

Piper Sandler Reiterates Neutral on Steris, Raises Price Target to $225

Wedbush analyst Henry Coffey reiterates UWM Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) with a Neutral and maintains $7 price target.

UWMC

Wedbush Reiterates Neutral on UWM Hldgs, Maintains $7 Price Target

Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) posted a loss for its <a href="https://www.benzinga.com/quote/RVNC/earnings">first quarter on Thursday</a>.
Revance Therapeutics posted a GAAP loss of 54 cents per share, compared to market expectations for a loss of 63 cents per share. The company's quarterly sales came in at $51.936 million versus estimates of $56.634 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
&#8220;We are very pleased to see the DAXXIFY strategy change continue to drive the desired momentum and market share gains. Notably, we saw a healthy uptick in volume both on a year-on-year basis, where aesthetic units sold increased by 105%, and on a sequential quarterly basis where aesthetic units sold increased by 7% despite traditional Q4 to Q1 seasonality. The positive impact of our strategy change was further reflected in our market share gains where DAXXIFY&#8217;s share increased from 3.0% in Q4&#8217;23 to 3.7% in Q1&#8217;24.1 DAXXIFY&#8217;s net revenue was $22.1 million for the quarter, after a reduction of $2.0 million related to a consumer coupon program. In addition, the RHA Collection continued to outpace the market growing share from 9.1% in Q4&#8217;23 to 9.8%1 in Q1&#8217;24, against the backdrop of a soft filler market,&#8221; said Mark J. Foley, President and Chief Executive Officer.
Revance continues to expect 2024 total net product revenue, which includes sales of DAXXIFY and RHA collection, to be at least $280 million.
Revance Therapeutics shares rose 0.5% to close at $4.29 on Thursday.
These analysts made changes to their price targets on Revance Therapeutics following earnings announcement.
<ul>
<li>Needham cut the price target on Revance Therapeutics from $18 to $12. Needham analyst Serge Belanger maintained a Buy rating.</li>
<li>Mizuho slashed the price target on Revance Therapeutics from $9 to $8. Mizuho analyst Vamil Divan maintained a Neutral rating.</li>
</ul>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38757985/top-2-materials-stocks-that-could-blast-off-this-quarter">Top 2 Materials Stocks That Could Blast Off This Quarter</a>

AKAM

RVNC

These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results

Piper Sandler analyst David Amsellem reiterates Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Overweight and lowers the price target from $20 to $11.

Piper Sandler Reiterates Overweight on Revance Therapeutics, Lowers Price Target to $11

Thailand&#8217;s Prime Minister Srettha Thavisin has declared his government&#8217;s intention to re-criminalize cannabis by the end of 2024, undoing the country´s <a href="https://www.benzinga.com/markets/cannabis/22/06/27631189/thailand-makes-marijuana-legal-here-are-dos-donts-you-need-to-know">2022 decision</a> to decriminalize the plant.
The initial decriminalization of cannabis had catalyzed the establishment of a robust industry, fostering thousands of dispensaries and attracting foreign investment into high-tech cannabis farms. A report by the University of the Thai Chamber of Commerce in 2022 even estimated the industry&#8217;s <a href="https://www.benzinga.com/markets/cannabis/22/11/29790158/cannabis-legalization-in-germany-and-thailand-gray-market-in-brooklyn-craft-weed-companies-in-or">potential value</a> at $1.2 billion by 2025. However, under the proposed changes, cannabis would be relabeled as a &#8220;category five&#8221; narcotic, making it illegal to &#8220;produce, sell, import, export, or possess&#8221; the plant for non-medical purposes.
<h3 class="wp-block-heading">Facing Protests And Legal Challenges</h3>
This announcement comes after Thavisin, a former real estate businessman who took office in August, shared on social media his directive for the Ministry of Health to permit only medical and health-related uses of cannabis. This comes in the context of announced efforts &#8220;to solve the drugs problem within 90 days&#8221; in an X post on Wednesday.
The re-criminalization move has already ignited backlash, <a href="https://time.com/6976768/thailand-cannabis-criminalization-law-protests-lawsuits/">reported </a>Time. Rattapon Sanrak, owner of the Bangkok-based Highland Cafe, voiced the frustration of many: &#8220;We're all doing everything by the book but then suddenly the book is going to change.&#8221;
Resistance measures have been prepared for months as the government´s move comes in a coordinated and preannounced effort. Community and industry members are threatening to organize street protests and class-action lawsuits to repel the sudden changes in the regulatory paradigm. The nearly 8000 Affected dispensaries will likely join in. These <a href="https://www.benzinga.com/markets/asia/24/02/37115420/thai-gov-delays-ban-on-cannabis-as-anxious-business-people-prepare-to-file-thousands-of-lawsuits">class-action lawsuits</a> were in January of this year.
The policy reversal risks not only legal pushback but economic repercussions, undermining the growth and stability of the nascent cannabis sector. This concern is shared by the advocacy group Writing Thailand's Cannabis Future, which announced a protest scheduled for May 16 in Bangkok.
Meanwhile, this week in a landmark <a href="https://www.benzinga.com/markets/cannabis/24/05/38703535/thailand-approves-opium-magic-mushrooms-for-medical-and-research-purposes">shift in drug policy</a>, Thailand&#8217;s Ministry of Public Health officially sanctioned the medical and research use of opium and psilocybin mushrooms, commonly known as magic mushrooms.
<h3 class="wp-block-heading">Thailand´s U-Turn</h3>
The new government&#8217;s conservative approach contrasts sharply with its prior liberal stance, which positioned the Kingdom as a pioneer in cannabis reform within Southeast Asia. The 2022 decision made Thailand the<a href="https://www.benzinga.com/markets/cannabis/22/06/27708219/cannabis-legalization-in-thailand-pros-and-concerns-about-its-uses"> first country </a>in Southeast Asia to legalize recreational cannabis and the third in the world after Canada and Uruguay. This liberalization was originally intended to enhance agricultural income and promote wellness tourism.
Thavisin made clear his stance towards cannabis <a href="https://www.benzinga.com/markets/cannabis/24/01/36549341/thailand-takes-a-u-turn-on-weed-spains-health-minister-on-mmj-reform-and-more-global-cannabis-up">before </a>the May 2023 election when Pheu Thai Party came out against &#8220;full cannabis legalization.&#8221; Pushing the anti-cannabis agenda, Health Minister Cholnan Srikaew signed a bill to modify the cannabis legislation. &#8220;The use for fun is considered wrong,&#8221; stated Srikaew after people complained about <a href="https://www.benzinga.com/markets/cannabis/24/02/36960066/thai-gov-rushes-to-ban-cannabis-after-weed-smelling-coldplay-concert-more-pot-updates">smelling weed</a> in a Coldplay concert on February this year.
The Bhumjaithai Party, instrumental in the 2022 decriminalization under the previous administration but now a part of Thavisin&#8217;s government, argues that regulating recreational use would be more effective than outright prohibition. 
Should they hold, these changes will not affect the medical and research use of cannabis which is still approved. As this policy debate unfolds, the consequences will likely resonate far beyond Thailand&#8217;s borders, possibly influencing regional drug policy.

Cannabis

Government

Regulations

Thailand's Shift: New Prime Minister Plans To Criminalize Cannabis Reversing 2022 Decision

Barclays analyst Peter Lawson upgrades Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) from Equal-Weight to Overweight and maintains the price target from $15 to $15.

Upgrades

RLAY

Barclays Upgrades Relay Therapeutics to Overweight, Maintains Price Target to $15

Wedbush analyst Jay McCanless reiterates Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) with a Outperform and maintains $17 price target.

GHLD

Wedbush Reiterates Outperform on Guild Holdings, Maintains $17 Price Target

Piper Sandler analyst Kashy Harrison maintains Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) with a Underweight and lowers the price target from $2.9 to $2.5.

PLUG

Piper Sandler Maintains Underweight on Plug Power, Lowers Price Target to $2.5

In the ongoing legal skirmish between Kraken and the <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38723057/gary-gensler-led-sec-a-source-of-frustration-for-robinhood-ceo-vlad-tenev-says-theyve-held">U.S. Securities and Exchange Commission</a> (SEC), the cryptocurrency exchange has challenged the SEC's linguistic precision in a fresh legal brief.
What Happened: Kraken's defense, detailed in a response filed last Thursday, criticizes the SEC for not specifying the exact nature of the &#8220;investment contracts&#8221; involved in the activities on its platform, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-05-10/kraken-battles-sec-over-investment-concept-wording-in-filing?embedded-checkout=true">reported</a>.
Instead, the SEC referred ambiguously to &#8220;investment concepts&#8221; and &#8220;ecosystems.&#8221;
Kraken&#8217;s legal contention highlights the SEC&#8217;s apparent lexical missteps in their April response to Kraken&#8217;s motion to dismiss the case. 
The exchange argues that the SEC's failure to properly define the securities involved undermines the legitimacy of the regulatory body's accusations. 
The SEC's own words from an earlier filing were invoked against it: "the words themselves do not delimit the security type because ‘the reach of the act does not stop with the obvious and commonplace'," a reference intended to underline the broad scope of regulatory reach, yet ironically pointing to the vague terminology used by the agency.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38736514/donald-trump-says-you-better-vote-for-him-if-youre-pro-crypto-but-has-he-always-been-fine-">Donald Trump Says &#8216;You Better Vote&#8217; For Him If You&#8217;re Pro-Crypto: But Has He Always Been &#8216;Fine With It&#8217;?</a>
The ongoing dispute with Kraken is part of a broader SEC initiative targeting major players in the cryptocurrency industry. Similar regulatory scrutiny has been applied to other key industry entities like Binance Holdings (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>) and Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>).
Despite the aggressive regulatory stance, Kraken settled with the SEC on separate charges related to its staking services earlier in February 2023.
What&#8217;s Next: As industry stakeholders prepare for the Benzinga conference, the outcomes of cases like Kraken's may influence discussions on how digital asset companies navigate the complex web of U.S. securities laws.
The escalating regulatory scrutiny within the crypto industry underscores the themes that will be pivotal at the upcoming Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19. 
The event is set to delve deeply into the intersection of regulation and innovation within the digital assets space.
Insights from these legal battles are expected to be key topics at the event, offering attendees a clearer perspective on the future <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38728088/jpmorgan-analysts-optimistic-about-future-approval-of-spot-ether-etfs-despite-regulatory-h">regulatory landscape for digital assets.</a>
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38733156/house-challenges-sec-over-crypto-custody-rules-biden-vows-blockade">House Challenges SEC Over Crypto Custody Rules, Biden Vows Blockade</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

COIN

SEC Accusations Misworded? Kraken Fights Back In Crypto Regulation Clash

Barclays analyst Leon Wang downgrades RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) from Overweight to Equal-Weight and lowers the price target from $13 to $4.

RAPT

Barclays Downgrades RAPT Therapeutics to Equal-Weight, Lowers Price Target to $4

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and lowers the price target from $51 to $50.

XENE

Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $50

Piper Sandler analyst Peter Keith maintains Savers Value Village (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) with a Overweight and lowers the price target from $24 to $19.

Piper Sandler Maintains Overweight on Savers Value Village, Lowers Price Target to $19

Jefferies analyst Matthew Taylor maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $255 to $260.

PODD

Jefferies Maintains Buy on Insulet, Raises Price Target to $260

Piper Sandler analyst Edward Tenthoff maintains Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) with a Neutral and lowers the price target from $7 to $4.

FATE

Piper Sandler Maintains Neutral on Fate Therapeutics, Lowers Price Target to $4

Jefferies analyst James Grzinic assumes Ferrari (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>) with a Hold rating and lowers Price Target of $403.

Initiation

RACE

Jefferies Assumes Ferrari at Hold, Lowers Price Target of $403

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the day with a breakdown of the biggest pre-market stock movers for Thursday!
Moving stocks this morning are share distributions, a merger approval, a stock offering, and more.
Let&rsquo;s get into that news down below!

<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>
<ol>
<li>Safe &amp; Green (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgbx-stock-quote/">SGBX</a>) stock is rocketing more than 126% after announcing Sept. 27, 2023, <a href="https://www.nasdaq.com/press-release/safe-green-holdings-corp.-announces-distribution-date-of-september-27-2023-for">as a distribution date for shares</a>.</li>
<li>Near Intelligence (NASDAQ:<a href="https://investorplace.com/stock-quotes/nir-stock-quote/">NIR</a>) shares are soaring over 35% alongside heavy pre-market trading today.</li>
<li>Scilex (NASDAQ:<a href="https://investorplace.com/stock-quotes/sclx-stock-quote/">SCLX</a>) stock is surging more than 34% without any clear news this morning.</li>
<li>Murphy Canyon Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/murf-stock-quote/">MURF</a>) shares are rising over 24% after <a href="https://www.nasdaq.com/press-release/murphy-canyon-acquisition-corp.-announces-stockholder-approval-of-the-proposed">getting shareholder approval</a> for its merger with Conduit Pharmaceuticals Limited.</li>
<li>Neptune Wellness Solutions (NASDAQ:<a href="https://investorplace.com/stock-quotes/nept-stock-quote/">NEPT</a>) stock is gaining more than 22% on Thursday morning.</li>
<li>TradeUP Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/uptd-stock-quote/">UPTD</a>) shares are climbing over 22% as it continues to rally <a href="https://finance.yahoo.com/news/tradeup-acquisition-corp-announces-extension-210000995.html">on an extended deadline</a>.</li>
<li>Alliance Entertainment (NASDAQ:<a href="https://investorplace.com/stock-quotes/aent-stock-quote/">AENT</a>) stock is increasing more than 19% after announcing <a href="https://www.nasdaq.com/press-release/alliance-entertainment-to-present-at-ld-micro-main-event-xvi-conference-on-october-3">a presentation in October</a>.</li>
<li>Antelope Entertainment (NASDAQ:<a href="https://investorplace.com/stock-quotes/aehl-stock-quote/">AEHL</a>) shares are jumping over 19% on Thursday morning.</li>
<li>MSP Recovery (NASDAQ:<a href="https://investorplace.com/stock-quotes/lifw-stock-quote/">LIFW</a>) stock is getting a more than 14% boost following a <a href="https://investorplace.com/2023/09/why-is-msp-recovery-lifw-stock-up-100-today/">massive rally on Wednesday</a>.</li>
<li>Vascular Biogenics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vblt-stock-quote/">VBLT</a>) shares are up 14% this morning.</li>
</ol>
<h2>10 Top Losers</h2>
<ol>
<li>Heart Test Laboratories (NASDAQ:<a href="https://investorplace.com/stock-quotes/hscs-stock-quote/">HSCS</a>) stock is diving over 15% alongside a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317759380&amp;type=PDF&amp;symbol=HSCS&amp;cdn=7f2423a9156e31f754d9d62ed11aaf8a&amp;companyName=Heart+Test+Laboratories+Inc.&amp;formType=D&amp;formDescription=Notice+of+Exempt+Offering+of+Securities&amp;dateFiled=2023-09-20">stock offering filing</a>.</li>
<li>TransCode Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) shares are tumbling more than 15% following a rally yesterday.</li>
<li>Brenmiller Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnrg-stock-quote/">BNRG</a>) stock is taking an over 14% beating without any clear news this morning.</li>
<li>Akerna (NASDAQ:<a href="https://investorplace.com/stock-quotes/kern-stock-quote/">KERN</a>) shares are sliding more than 13% on Thursday morning.</li>
<li>ARB IOT Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/arbb-stock-quote/">ARBB</a>) stock is decreasing over 12% today.</li>
<li>Avinger (NASDAQ:<a href="https://investorplace.com/stock-quotes/avgr-stock-quote/">AVGR</a>) shares are falling more than 12% after rallying on a <a href="https://finance.yahoo.com/news/avinger-initiates-full-commercial-launch-120000962.html">commercial product launch</a>.</li>
<li>Fitell (NASDAQ:<a href="https://investorplace.com/stock-quotes/ftel-stock-quote/">FTEL</a>) stock is dropping over 11% roughly one month after its <a href="https://finance.yahoo.com/news/fitell-corporation-announces-closing-15-154500966.html">initial public offering (IPO)</a>.</li>
<li>Histogen (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsto-stock-quote/">HSTO</a>) shares are sliding more than 11% as it heads for <a href="https://finance.yahoo.com/news/histogen-announces-board-approval-complete-200500835.html">liquidation and dissolution</a>.</li>
<li>Seelos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/seel-stock-quote/">SEEL</a>) stock is dipping over 11% following <a href="https://www.marketwatch.com/story/seelos-therapeutics-stock-slides-36-after-trial-of-treatment-for-suicidal-ideation-has-too-few-patients-to-meet-endpoint-3df191e8">lackluster clinical trial results</a>.</li>
<li>36KR (NASDAQ:<a href="https://investorplace.com/stock-quotes/krkr-stock-quote/">KRKR</a>) shares close out our pre-market stock movers down 10% today.</li>
</ol>
On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
<ul>
<li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT758392">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT758390">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT758396">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
</ul>
<div>
<div>
<div></div>
<div></div>
</div>
</div>
The post <a href="https://investorplace.com/2023/09/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-sept-21st/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

IMAX, SBGI among major communication services gainers; KRKR, TKO among losers

36Kr Holdings GAAP EPADS of -$0.062, revenue of $13.3M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!



Moving stocks are new deals, earnings reports, and share offerings.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Hempacco (NASDAQ:<a href="https://investorplace.com/stock-quotes/hpco-stock-quote/">HPCO</a>) stock is rocketing more than 67% after <a href="https://www.nasdaq.com/press-release/hempacco-expands-its-reach-to-india-and-thailand-signing-exclusive-master">signing a new distribution agreement</a>.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) shares are soaring 43% as it <a href="https://investorplace.com/2023/12/why-is-microalgo-mlgo-stock-up-55-today/">continues a recent rally</a>.</li>



<li>Altisource Asset Management (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aamc-stock-quote/">AAMC</a>) stock is surging over 20% following <a href="https://www.nasdaq.com/press-release/altisource-asset-management-corporation-reports-key-ruling-in-blackrock-and-pimco">a lawsuit update</a>.</li>



<li>Oblong (NASDAQ:<a href="https://investorplace.com/stock-quotes/oblg-stock-quote/">OBLG</a>) shares are rising more than 17% alongside heavy trading.</li>



<li>Barnes &amp; Noble Education (NYSE:<a href="https://investorplace.com/stock-quotes/bned-stock-quote/">BNED</a>) stock is gaining over 17% with the release of its <a href="https://www.nasdaq.com/press-release/barnes-noble-education-reports-second-quarter-fiscal-year-2024-financial-results-2023">fiscal Q2 earnings report</a>.</li>



<li>AerSale (NASDAQ:<a href="https://investorplace.com/stock-quotes/asle-stock-quote/">ASLE</a>) shares are increasing more than 16% after getting a <a href="https://www.nasdaq.com/press-release/aersaler-receives-boeing-737ng-supplemental-type-certificate-for-its-enhanced-flight">737NG supplemental certificate</a>.</li>



<li>Parts ID (NYSEMKT:<a href="https://investorplace.com/stock-quotes/id-stock-quote/">ID</a>) stock is heading over 14% higher alongside <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317912997&amp;type=PDF&amp;symbol=ID&amp;cdn=6612bfe828c1a332523110a4b54f7d0e&amp;companyName=PARTS+iD+Inc.+Class+A&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-12-06">a financing deal</a> with Riverside Capital NY.</li>



<li>TLGY Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlgy-stock-quote/">TLGY</a>) shares are climbing more than 14% on Thursday morning.</li>



<li>Cerevel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cere-stock-quote/">CERE</a>) stock is jumping 14% as AbbVie (NYSE:<a href="https://investorplace.com/stock-quotes/abbv-stock-quote/">ABBV</a>) <a href="https://www.nasdaq.com/press-release/abbvie-to-acquire-cerevel-therapeutics-in-transformative-transaction-to-strengthen">acquires the company</a>. </li>



<li>36KR Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/krkr-stock-quote/">KRKR</a>) shares are up over 13% with its <a href="https://www.nasdaq.com/press-release/36kr-holdings-inc.-reports-third-quarter-2023-unaudited-financial-results-2023-12-07">Q3 2023 earnings report</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Troika Media Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/trka-stock-quote/">TRKA</a>) stock is crashing more than 55% after announcing a <a href="https://www.nasdaq.com/press-release/troika-media-group-inc.-announces-strategic-chapter-11-filing-and-sale-to-blue-torch">Chapter 11 filing and sale plans</a>.</li>



<li>ZyVersa Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/zvsa-stock-quote/">ZVSA</a>) shares are retreating over 41% after <a href="https://www.nasdaq.com/press-release/zyversa-therapeutics-inc.-announces-pricing-of-%245.0-million-public-offering-2023-12">pricing a stock offering</a>.</li>



<li>Red Cat (NASDAQ:<a href="https://investorplace.com/stock-quotes/rcat-stock-quote/">RCAT</a>) stock is plummeting close to 33% as it also <a href="https://seekingalpha.com/news/4044165-red-cat-holdings-stock-dips-on-pricing-8-million-capital-raise-via-stock-offering?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">prices a share offering</a>.</li>



<li>Bit Brother (NASDAQ:<a href="https://investorplace.com/stock-quotes/bets-stock-quote/">BETS</a>) shares are diving 30% on a <a href="https://seekingalpha.com/news/4043573-bit-brother-to-raise-12m-via-stock-and-warrants-offering">stock and warrants offering</a>.</li>



<li>Sprinklr (NYSE:<a href="https://investorplace.com/stock-quotes/cxm-stock-quote/">CXM</a>) stock is tumbling more than 25% <a href="https://seekingalpha.com/news/4044109-sprinklr-non-gaap-eps-of-0_12-beats-0_05-revenue-of-186_3m-beats-5_88m">despite a recent earnings beat</a>.</li>



<li>Baiyu (NASDAQ:<a href="https://investorplace.com/stock-quotes/byu-stock-quote/">BYU</a>) shares are taking an over 23% beating <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317911768&amp;type=PDF&amp;symbol=BYU&amp;cdn=2d217588152e75dd156bcd8f04605b44&amp;companyName=BAIYU+Holdings+Inc.&amp;formType=SC+13D&amp;formDescription=General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2023-12-06">despite a recent investment</a>.</li>



<li>Wave Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/wve-stock-quote/">WVE</a>) stock is sliding more than 22% after <a href="https://www.nasdaq.com/press-release/wave-life-sciences-prices-%24100-million-public-offering-of-ordinary-shares-2023-12-07">pricing a public offering</a>.</li>



<li>FSD Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/huge-stock-quote/">HUGE</a>) shares are dropping over 17% on Thursday morning.</li>



<li>Greenbrook TMS (NASDAQ:<a href="https://investorplace.com/stock-quotes/gbnh-stock-quote/">GBNH</a>) stock is decreasing more than 17% following a rally yesterday.</li>



<li>Starbox (NASDAQ:<a href="https://investorplace.com/stock-quotes/stbx-stock-quote/">STBX</a>) shares close out our pre-market stock movers down over 16%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766529">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-dec-7th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

36Kr Holdings Inc. (KRKR) Q3 2023 Earnings Call Transcript

36Kr Holdings GAAP EPADS of -$0.06, revenue of $14.6M

36Kr Holdings Inc Adr Class A (KRKR) has released an update. 36Kr Holdings Inc. has reported a 7% increase in fourth-quarter revenue to RMB 103.3 m...

36Kr Reports Revenue Growth and Profit Margin Gains

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
36KR Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/krkr-stock-quote/">KRKR</a>) just reported results for the fourth quarter of 2023.<ul><li>36KR Holdings reported earnings per share of -6.3 cents.</li><li>The company reported revenue of $14.55 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/krkr-stock-earnings-36kr-holdings-for-q4-of-2023/">KRKR Stock Earnings: 36KR Holdings Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KRKR Stock Earnings: 36KR Holdings Reported Results for Q4 2023

36Kr Holdings Inc. (KRKR) Q4 2023 Earnings Call Transcript

36Kr Holdings Inc Adr Class A (KRKR) has released an update. 36Kr Holdings Inc., a leading platform for China's New Economy sectors, has received a...

36Kr Holdings Transitions to Nasdaq Capital Market

AMCX

ASLE

BETS

BNED

BNRG

CERE

CMLS

GBNH

HPCO

HRYU

HSTO

HUGE

IMAX

MLGO

OBLG

RCAT

SBGI

SCLX

STBX

TLGY

TRKA

UPXI

VBLT

ZVSA

Contracts

Press Releases

36Kr Enters into Strategic Partnership with Baidu to Empower Growth with AI Applications

Fintech

36Kr Holdings Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 31, 2023

36Kr Holdings Inc. Reports Second Quarter 2023 Unaudited Financial Results

36Kr Holdings Inc. to Report Third Quarter 2023 Financial Results on Thursday, December 7, 2023

36Kr Holdings Inc. Reports Third Quarter 2023 Unaudited Financial Results

36Kr Holding Inc. Announces Changes to Board of Directors

36Kr Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on Thursday, March 28, 2024

36Kr Holdings Inc. Reports Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results

36Kr Holdings Inc. Files 2023 Annual Report on Form 20-F

BIDU

Antelope Enterprise Holdings Limited - Class A Ordinary Shares

Antelope Ent Hldgs

The Arena Group Holdings, Inc. Common Stock

Arena Group Holdings

BuzzFeed

Cheer Holding

Fangdd Network Group Ltd. - American Depositary Shares

Fangdd Network Group

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Phoenix New Media

Hanryu Holdings

-

-

-

-

-

-

-

-

-

-

-

-

-

-

36KR Holdings Stock (NASDAQ:KRKR), Short Interest Report

People Also Watch